Advertisement

European cohorts of older HIV adults: POPPY, AGEhIV, GEPPO, COBRA and FUNCFRAIL

  • Jovana Milic
  • Magdalena Russwurm
  • Ana Cerezales Calvino
  • Fátima Brañas
  • Matilde Sánchez-Conde
  • Giovanni GuaraldiEmail author
Special Article

Key summary points

Aim

The aim of this paper is to describe ongoing aging HIV cohorts that include older (> 50 years) or geriatric (> 65 years) people living with HIV and present the key results obtained in those studies.

Findings

Existing aging HIV cohorts are pointing out unmet medical needs of OALWH. However, there are no studies designed to detect best ART strategies in this population and various outcomes that go beyond the viro-immunological success, such as frailty, geriatric syndromes, physical function, disability, quality of life and healthy aging are still not routinely part of aging cohorts.

Message

The already present demographic transition affecting PLWH are not paralleled by significant changes in the clinical management. In order to better describe aging trajectories in this population, it is essential to collect and measure immunological biomarkers. Results from aging HIV observational studies can also inspire randomized clinical trials.

Abstract

Aim

The recent and rapid demographic changes affecting people living with HIV (PLWH) produced a subset of older adults demanding a prompt response both in clinical practice and research setting. The scientific community had to properly design studies that include older adults living with HIV (OALWH), aged > 50 years, or geriatric PLWH, aged > 65 years to explore the interaction between aging and HIV itself, antiretroviral therapy (ART) and non-infectious co-morbidities (NICM). Choosing between these two types of cohorts may represent a trap, but also a possibility to measure different outcomes and obtain different evidence. The aim of this paper is to describe ongoing aging HIV cohorts that include older or geriatric PLWH and present the key results obtained in those studies.

Methods

So far, in Europe, there are ongoing cohorts that comprise OALWH or geriatric PLWH: AGEhIV, POPPY, GEPPO, FUNCFRAIL and COBRA. We will summarize crucial findings from each study published up to now, which will be categorized as results related to HIV and ART, NICM and geriatric syndromes.

Results

Existing aging HIV cohorts are pointing out unmet medical needs of OALWH but are still not representative of the entire European HIV aging epidemic. Moreover, there are no studies designed to detect best ART strategies in this population and various outcomes that go beyond the viro-immunological success are still not routinely part of aging cohorts.

Conclusion

Results from aging cohorts with outcomes that go beyond the undetectability will pave the way to health care providers to encounter unmet needs of OALWH.

Keywords

Observational HIV study Aging Older adults Geriatric people living with HIV 

Notes

Funding

There was no dedicated funding for this study.

Compliance with ethical standards

Conflict of interest

GG is an investigator in GEPPO cohort and a collaborator in COBRA cohort. FB and MSC are investigators in FUNCFRAIL cohort. All other authors report no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

References

  1. 1.
    Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik JM (2000) Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 48(12):1618–1625Google Scholar
  2. 2.
    Börsch-Supan A, Brugiavini A, Jürges H, Kapteyn A, Mackenbach J, Siegrist J, Weber G (eds) (2008) First results from the Survey of Health, Aging and Retirement in Europe (2004–2007). Starting the longitudinal dimension. Mannheim Research Institute for the Economics of Aging (MEA), Mannheim. http://www.share-project.org/uploads/tx_sharepublications/BuchSHAREganz250808.pdf. Accessed 27 Dec 2018
  3. 3.
    Regan S, Meigs JB, Grinspoon SK, Triant VA (2016) Determinants of smoking and quitting in HIV-infected individuals. PLoS One 11(4):e0153103Google Scholar
  4. 4.
    van Kesteren NM, Hospers HJ, Kok G (2007) Sexual risk behavior among HIV-positive men who have sex with men: a literature review. Patient Educ Couns 65(1):5–20Google Scholar
  5. 5.
    De Francesco D, Underwood J, Post FA, Vera JH, Williams I, Boffito M et al (2016) Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis 16(1):617Google Scholar
  6. 6.
    De Francesco D, Wit FW, Cole JH et al (2018) The ‘COmorBidity in Relation to AIDS’ (COBRA) cohort: design, methods and participant characteristics. PLoS One 13(3):e0191791Google Scholar
  7. 7.
    Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P, AGEhIV Cohort Study Group (2014) Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 59(12):1787–1797Google Scholar
  8. 8.
    Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53(11):1120–1126Google Scholar
  9. 9.
    Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman RB (eds) (2001) Designing clinical research: an epidemiologic approach, 2nd edn. Lippincott Williams and Wilkins, BaltimoreGoogle Scholar
  10. 10.
    Chambers LA, Wilson MG, Rueda S et al (2014) Evidence informing the INTERSECTION of HIV, aging and health: a scoping review. AIDS Behav 18(4):661–675Google Scholar
  11. 11.
    Lazarus JV, Nielsen KK (2010) HIV and people 50 years old in Europe. HIV Med 11(7):479–481Google Scholar
  12. 12.
    Cooperman NA, Arnsten JH, Klein RS (2007) Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection. AIDS Educ Prev 19(4):321–333Google Scholar
  13. 13.
    CDC, Center for Disease Control and Prevention. HIV/ AIDS among Persons Aged 50 and Older. https://www.cdc.gov/hiv/group/age/olderamericans/index.html. Accessed 29 Dec 2018
  14. 14.
    Mugavero MJ, Napravnik S, Cole SR et al (2011) Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 539:927–935Google Scholar
  15. 15.
    Wright ST, Hoy J, Mulhall B et al (2014) Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 661:55–64Google Scholar
  16. 16.
    Guaraldi G, Raggi P (2017) Atherosclerosis in frailty: not frailty in atherosclerosis. Atherosclerosis. 266:226–227Google Scholar
  17. 17.
    Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, Anderson J, Asboe D, Garvey L, Vera J, Williams I, Johnson M, Babalis D, De Francesco D, Winston A, Sabin CA (2018) Cohort profile: the pharmacokinetic and clinical observations in people over fifty (POPPY) study. Int J Epidemiol 47(5):1391–1392Google Scholar
  18. 18.
    Spanish Cohort of Patients With HIV Infection Older Than 50 Years for the Study of Fragility and Physical Function (FUNCFRAIL). https://clinicaltrials.gov/ct2/show/NCT03558438. Accessed 27 Dec 2018
  19. 19.
    Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G, GEPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group (2017) Role of normalized T-cell subsets in predicting comorbidities in a large cohort of geriatric HIV-infected patients. J Acquir Immune Defic Syndr 76(3):338–342Google Scholar
  20. 20.
    Boccara F (2017) Cardiovascular health in an aging HIV population. AIDS 31:S157–S163Google Scholar
  21. 21.
    Dalla Pria A, Merchant S, Bower M (2017) Oncological challenges for an ageing population living with HIV. AIDS 31:S185–S189Google Scholar
  22. 22.
    Althoff KN, McGinnis KA, Wyatt CM et al (2015) Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 60:627–638Google Scholar
  23. 23.
    Smit M, Brinkman K, Geerlings S et al (2015) Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 15:810–818Google Scholar
  24. 24.
    Gonciulea A, Wang R, Althoff KN et al (2017) An increased rate of fracture occurs a decade earlier in HIV compared with HIV men. AIDS 31:1435–1443Google Scholar
  25. 25.
    Guaraldi G, Brothers TD, Zona S et al (2015) A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS. 29(13):1633–1641Google Scholar
  26. 26.
    Guaraldi G, Malagoli A, Theou O et al (2017) Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. HIV Med 18(10):764–771Google Scholar
  27. 27.
    Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156Google Scholar
  28. 28.
    Maruff P, Thomas E, Cysique L et al (2009) Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24:165–178Google Scholar
  29. 29.
    Blackstone K, Moore DJ, Franklin DR et al (2012) Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 26:894–908Google Scholar
  30. 30.
    Kim WJ, Ku NS, Lee YJ, Ahn JY, Kim SB, Ahn HW, Hong KW, Song JY, Cheong HJ, Kim WJ, Kim JM, Namkoong K, Choi JY, Kim E (2016) Utility of the Montreal Cognitive Assessment (MoCA) and its subset in HIV-associated neurocognitive disorder (HAND) screening. J Psychosom Res 80:53–57Google Scholar
  31. 31.
    Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155Google Scholar
  32. 32.
    Justice AC (2010) HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 7:69–76Google Scholar
  33. 33.
    Deeks SG, Tracy R, Douek DC (2013) Systemic effects of inflammation on health during chronic HIV infection. Immunity 39:633–645Google Scholar
  34. 34.
    Cobos Jiménez V, Wit FW, Joerink M, Maurer I, Harskamp AM, Schouten J, Prins M, van Leeuwen EM, Booiman T, Deeks SG, Reiss P, Kootstra NA, AGEhIV Study Group (2016) T-Cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment. J Infect Dis 214(2):216–225Google Scholar
  35. 35.
    Booiman T, Wit FW, Girigorie AF, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Franceschi C, Deeks SG, Winston A, Reiss P, Kootstra NA, Co-morBidity in Relation to Aids (COBRA) Collaboration (2017) Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. PLoS One 12(8):e0183357Google Scholar
  36. 36.
    De Francesco D, Wit FW, Bürkle A, Oehlke S, Kootstra NA, Winston A, Franceschi C, Garagnani P, Pirazzini C, Libert C, Grune T, Weber D, Jansen EHJM, Sabin CA, Reiss P, the Co-morBidity in Relation to AIDS (COBRA) Collaboration (2019) Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS 33(2):259–268Google Scholar
  37. 37.
    Rasmussen LD, Helleberg M, May MT et al (2015) Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis 60(9):1415–1423Google Scholar
  38. 38.
    Kooij KW, Wit FW, Booiman T, van der Valk M, Schim van der Loeff MF, Kootstra NA, Reiss P, AGEhIV Cohort Study Group (2016) Cigarette smoking and inflammation, monocyte activation, and coagulation in HIV-infected individuals receiving antiretroviral therapy compared with uninfected individuals. J Infect Dis 214(12):1817–1821Google Scholar
  39. 39.
    Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Garagnani P, Pirazzini C, Franceschi C, Fuchs D, Gisslén M, Winston A, Reiss P, Kootstra NA, Comorbidity in Relation to AIDS (COBRA) Collaboration (2017) High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in cerebrospinal fluid. Open Forum Infect Dis 4(3):ofx108Google Scholar
  40. 40.
    Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, Prins M, Reiss P, van der Valk M, AGEhIV Cohort Study Group (2016) Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS 30(11):1771–1780Google Scholar
  41. 41.
    Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G, GEPPO Study Group (2017) Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother 72(10):2879–2886Google Scholar
  42. 42.
    Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort Study (2018) Patterns of co-occurring comorbidities in people living with HIV. Open Forum Infect Dis 5(11):ofy272Google Scholar
  43. 43.
    van Zoest RA, van der Valk M, Wit FW et al (2017) Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. Eur J Prev Cardiol. 24(12):1297–1307Google Scholar
  44. 44.
    van Zoest RA, Wit FW, Kooij KW, van der Valk M, Schouten J, Kootstra NA, Wiersinga WJ, Prins M, van den Born BJ, Reiss P, AGEhIV Cohort Study Group (2016) Higher prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is associated with changes in body composition and prior stavudine exposure. Clin Infect Dis 63(2):205–213Google Scholar
  45. 45.
    Kooij KW, Schouten J, Wit FW, van der Valk M, Kootstra NA, Stolte IG, van der Meer JT, Prins M, Grobbee DE, van den Born BJ, Reiss P (2016) Difference in aortic stiffness between treated middle-aged HIV Type 1-infected and uninfected individuals largely explained by traditional cardiovascular risk factors, with an additional contribution of prior advanced immunodeficiency. J Acquir Immune Defic Syndr 73(1):55–62Google Scholar
  46. 46.
    Kooij KW, Vogt L, Wit FWNM, van der Valk M, van Zoest RA, Goorhuis A, Prins M, Post FA, Reiss P, AGEhIV Cohort Study (2017) Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. J Infect Dis 216(6):622–631Google Scholar
  47. 47.
    Kooij KW, Wit FW, Bisschop PH, Schouten J, Stolte IG, Prins M, van der Valk M, Prins JM, van Eck-Smit BL, Lips P, Reiss P, AGEhIV Cohort Study group (2015) Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis 211(4):539–548Google Scholar
  48. 48.
    Dijkstra M, van Lunsen RHW, Kooij KW, Davidovich U, van Zoest RA, Wit FWMN, Prins M, Reiss P, Schim van der Loeff MF, AGEhIV Cohort Study Group (2018) HIV-1 status is independently associated with decreased erectile function among middle-aged MSM in the era of combination antiretroviral therapy. AIDS 32(9):1137–1146Google Scholar
  49. 49.
    Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G (2018) The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years. BMC Geriatr 18(1):99Google Scholar
  50. 50.
    Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(1789):1799Google Scholar
  51. 51.
    Gisslen M, Price RW, Nilsson S (2011) The definition of HIV associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 11:356Google Scholar
  52. 52.
    Su T, Schouten J, Geurtsen GJ, Wit FW, Stolte IG, Prins M, Portegies P, Caan MW, Reiss P, Majoie CB, Schmand BA, AGEhIV Cohort Study Group (2015) Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection. AIDS 29(5):547–557Google Scholar
  53. 53.
    Schouten J, Su T, Wit FW, Kootstra NA, Caan MW, Geurtsen GJ, Schmand BA, Stolte IG, Prins M, Majoie CB, Portegies P, Reiss P, AGEhIV Study Group (2016) Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral. AIDS 30(7):1027–1038Google Scholar
  54. 54.
    Underwood J, De Francesco D, Leech R, Sabin CA, Winston A, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study (2018) Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. PLoS One 13(4):e0194760Google Scholar
  55. 55.
    Underwood J, Cole JH, Caan M, De Francesco D, Leech R, van Zoest RA, Su T, Geurtsen GJ, Schmand BA, Portegies P, Prins M, Wit FWNM, Sabin CA, Majoie C, Reiss P, Winston A, Sharp DJ, Comorbidity in Relation to AIDS (COBRA) Collaboration (2017) Gray and white matter abnormalities in treated human immunodeficiency virus disease and their relationship to cognitive function. Clin Infect Dis 65(3):422–432Google Scholar
  56. 56.
    Underwood J, De Francesco D, Post FA, Vera JH, Williams I, Boffito M, Mallon PW, Anderson J, Sachikonye M, Sabin C, Winston A, Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study group (2017) Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV. HIV Med 18(5):363–369Google Scholar
  57. 57.
    Su T, Wit FW, Caan MW, Schouten J, Prins M, Geurtsen GJ, Cole JH, Sharp DJ, Richard E, Reneman L, Portegies P, Reiss P, Majoie CB, AGEhIV Cohort Study (2016) White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. AIDS 30(15):2329–2339Google Scholar
  58. 58.
    Su T, Mutsaerts HJ, Caan MW, Wit FW, Schouten J, Geurtsen GJ, Sharp DJ, Prins M, Richard E, Portegies P, Reiss P, Majoie CB, AGEhIV Cohort Study (2017) Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy. AIDS 31(6):847–856Google Scholar
  59. 59.
    van Zoest RA, Underwood J, De Francesco D, Sabin CA, Cole JH, Wit FW, Caan MWA, Kootstra NA, Fuchs D, Zetterberg H, Majoie CBLM, Portegies P, Winston A, Sharp DJ, Gisslén M, Reiss P, Comorbidity in Relation to AIDS (COBRA) Collaboration (2017) Structural brain abnormalities in successfully treated hiv infection: associations with disease and cerebrospinal fluid biomarkers. J Infect Dis 217(1):69–81Google Scholar
  60. 60.
    Cole JH, Caan MWA, Underwood J, De Francesco D, van Zoest RA, Wit FWNM, Mutsaerts HJMM, Leech R, Geurtsen GJ, Portegies P, Majoie CBLM, Schim van der Loeff MF, Sabin CA, Reiss P, Winston A, Sharp DJ, Comorbidity in Relations to AIDS (COBRA) Collaboration (2018) No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus: longitudinal neuroimaging results from the comorbidity in relation to AIDS (COBRA) Project. Clin Infect Dis 66(12):1899–1909Google Scholar
  61. 61.
    Cole JH, Underwood J, Caan MW, De Francesco D, van Zoest RA, Leech R, Wit FW, Portegies P, Geurtsen GJ, Schmand BA, Schim van der Loeff MF, Franceschi C, Sabin CA, Majoie CB, Winston A, Reiss P, Sharp DJ, COBRA collaboration (2017) Increased brain-predicted aging in treated HIV disease. Neurology 88(14):1349–1357Google Scholar
  62. 62.
    Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, Prins M, Falutz J, Reiss P, AGEhIV Cohort Study Group (2016) HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS 30(2):241–250Google Scholar
  63. 63.
    Langebeek N, Kooij KW, Wit FW, Stolte IG, Sprangers MAG, Reiss P, Nieuwkerk PT, \AGEhIV Cohort Study Group (2017) Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals. AIDS 31(10):1471–1481Google Scholar
  64. 64.
    Möller LM, Brands R, Sluiter JK, Schouten J, Wit FW, Reiss P, Prins M, Stolte IG (2016) Prevalence and determinants of insufficient work ability in older HIV-positive and HIV-negative workers. Int Arch Occup Environ Health 89(4):699–709Google Scholar

Copyright information

© European Geriatric Medicine Society 2019

Authors and Affiliations

  • Jovana Milic
    • 1
    • 2
  • Magdalena Russwurm
    • 3
  • Ana Cerezales Calvino
    • 4
  • Fátima Brañas
    • 5
  • Matilde Sánchez-Conde
    • 6
  • Giovanni Guaraldi
    • 1
    Email author
  1. 1.Modena HIV Metabolic Clinic, Infectious Diseases Unit, School of MedicineUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Clinical and Experimental Medicine PhD ProgramUniversity of Modena and Reggio EmiliaModenaItaly
  3. 3.Medical University of ViennaViennaAustria
  4. 4.University Hospital of A Coruña (CHUAC)La CorunaSpain
  5. 5.Geriatrics DepartmentHospital Universitario Infanta LeonorMadridSpain
  6. 6.Infectious Diseases DepartmentHospital Universitario Ramón y Cajal, IRYCISMadridSpain

Personalised recommendations